Psychedelic drug makers rally as Trump orders FDA to expedite reviews - Yahoo Finance
Quick Insights
The Bottom Line
Psychedelic drug makers' stocks are rising after President Trump ordered the FDA to expedite reviews.
AI Summary
President Trump has ordered the Food and Drug Administration (FDA) to expedite reviews of psychedelic drugs, leading to a rally among psychedelic drug makers. This directive signals a significant shift in federal policy regarding these substances, potentially accelerating their path to market for therapeutic uses. The move could open new avenues for mental health treatments, as companies developing psychedelics for conditions like PTSD and depression stand to benefit from faster regulatory approval. This action by the Trump administration reflects a growing interest in the potential medical applications of psychedelics.
What's Being Done
President Trump has ordered the FDA to expedite reviews for psychedelic drugs.
Source Coverage Map
2 of 43 tracked sources covered this story
Following this story?
Get notified when new coverage appears
Other Sources Covering This Story
1 sourceMultiple outlets have reported on this story. Compare perspectives from different sources.
This article is part of a story we're tracking:
Trump Administration's Push for Psychedelic Drug Treatments
President Donald Trump has signed an executive order to accelerate access to and research into psychedelic drug treatments. This move aims to expand the availability of substances like LSD, psilocybin, and ibogaine for mental health treatment and research.
Trump Administration's Psychedelic Drug Initiative
President Trump signed an executive order to accelerate access to psychedelic drug treatments and research for mental health. This initiative aims to expand the availability of substances like LSD, psilocybin, and ibogaine for medical use.
Trump's Executive Order on Psychedelic Research
President Trump signed an executive order to ease restrictions and accelerate research into psychedelics, including ibogaine, LSD, and psilocybin, for mental health treatments. This move aims to expand access to these substances and expedite their review process.
Trump's Psychedelics Research Initiative
President Trump signed an executive order to ease restrictions and accelerate research into psychedelics like ibogaine, LSD, and psilocybin for potential medical applications, particularly in mental health treatment. The initiative aims to expand access to these substances and expedite their review process.
Trump's Executive Order on Psychedelic Research
President Trump signed an executive order aimed at accelerating the federal review process for psychedelics. The order seeks to expand access to psychedelic drug treatments for mental health, specifically mentioning substances like ibogaine, LSD, and psilocybin.
Trump Administration Accelerates Psychedelic Drug Research
President Donald Trump has signed an executive order to fast-track the review and research of psychedelic drugs for mental health disorders. This move aims to accelerate access to treatments like psilocybin and ibogaine, with the President publicly endorsing their potential.
Trump Administration Accelerates Psychedelic Drug Research
President Donald Trump signed an executive order to accelerate research and review of psychedelic drugs like psilocybin and ibogaine for mental health treatments. This move aims to fast-track their potential medical applications, with figures like Joe Rogan joining the announcement.
Trump Administration's Psychedelic Drug Research Initiative
President Trump has signed an executive order to accelerate research and review of psychedelic drugs for mental health disorders, including psilocybin and ibogaine. This initiative aims to expand access to these therapies, with podcaster Joe Rogan reportedly influencing the decision.
Trump Executive Order on Psychedelic Drug Research
President Trump signed an executive order to accelerate research and access to psychedelic drug treatments for mental health disorders. The initiative aims to fast-track the review process for substances like psilocybin and ibogaine.
Trump Administration's Push for Psychedelic Drug Research
President Trump has signed an executive order to accelerate research and review processes for psychedelic-based therapies. This initiative, reportedly influenced by Joe Rogan, aims to loosen restrictions and explore the potential of psychedelics for mental health disorders.
Trump Administration's Psychedelic Drug Review
President Donald Trump has signed an executive order to accelerate the review and research of psychedelic-based therapies for mental health disorders. This move, reportedly influenced by figures like Joe Rogan, aims to fast-track access to treatments like ibogaine and psilocybin.
Trump Administration's Psychedelics Initiative
President Trump has signed an executive order to accelerate research and review of psychedelic drugs for mental health disorders, reportedly influenced by a text from podcaster Joe Rogan. This initiative aims to fast-track therapies like psilocybin and ibogaine.
Should this be getting more attention?
You Might Have Missed
Related stories from different sources and perspectives
PoliticsWhat to Know About Trump’s New Executive Order on Psychedelic Drugs
The order calls for the FDA to give expedited consideration to certain psychedelic drugs.
PoliticsTrump signs order to speed review of psychedelics, including the controversial drug ibogaine - AP News
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNUzlaeEZMcTdjcFV0aGpYZi11X2pLUTgzamxyX2NwMWFraldDYmNjdGZkQmVlbnYyNjVwOUZ1LXdhbzhzTUhvclFmVDAzZWEwd3RfTHZ1YzZmQTZ1M1RZLXlOcDlwV1lfQzhfNWY2S3NfQVd2NFZYRnhWRW5XMm93eVRqbnRSYVFQX2VYa2xpd3h1eUUzS2ZJVUVQMjUtRllYWHgwSEpMMDBrNWFEajBJMEN3?oc=5" target="_blank">Trump signs order to speed review of psychedelics, including the controversial drug ibogaine</a> <font color="#6f6f6f">AP News</font>
HealthFDA Commissioner Marty Makary breaks down Trump's executive order on psychedelics
President Trump has signed an executive order to expand research into psychedelic drugs for mental health treatment. Dr. Marty Makary, commissioner of the Food and Drug Administration, joins CBS News to discuss.
PoliticsJustice Jackson chides Supreme Court conservatives over 'oblivious' pro-Trump emergency orders - AP News
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSmh3bjRzUnc2ZS1wb19KQ3d1eUtfTS1KX1M1anctNDVhSWo3aF83NWNpOXRJV2hiYmc3aEgzUkNxekJmSlJfVlN4UVg4VTQ3M0txVDVfRld2NnI4S3hpZGZNX01ZRjhyeHFOZ29nTW9SeDQ5RkdBSVlpNHlSeklMbVFDX3YybkkzQnN3dHZ3SC1tUzBxR3JiSm1FVGdrUmQ3RFFPNUtjZkhXczlqNlJhaklXZEtJUlJPYVpn?oc=5" target="_blank">Justice Jackson chides Supreme Court conservatives over 'oblivious' pro-Trump emergency orders</a> <font color="#6f6f6f">AP News</font>
PoliticsWhile Trump lashes out at Spain, US Democrats join a progressive rally in Barcelona - AP News
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQeVJnVUZHUGNSWnRlVW05NllwQVk2ZVpYWVNWYlR4UV9UTm1Db3NEYW9xQWNWUmYycHNiTTNpd3VKTnJWajQ4WXRILW04UkRoeVZBdGpiU05tVk5VTjhjM3VqMGtzY2JDS3luV1JxSFRRdTRiZlJycXl0VmVnUE11NWFYbHE0T1NfcGZsM1RkYVVDZUptOE52and3aU9jYVV1bl8wOEdjemVncFU?oc=5" target="_blank">While Trump lashes out at Spain, progressive leaders rally in Barcelona to defend democracy</a> <font color="#6f6f6f">AP News</font>
HealthReport: Merck’s blockbuster cancer drug topped $200,000 a year under Trump
Despite the president’s plan to lower prescription medicine costs, the price of many of the most expensive drugs — including several immunotherapy treatments — have continued to rise.
Purdue Pharma expected to forfeit $225m as sentence in criminal opioids case
<p>Under settlement, Sackler family will pay state, local and Native American tribal governments, individual victims and others</p><ul><li><p><a href="https://www.theguardian.com/news/2026/feb/17/sign-up-for-the-breaking-news-us-email-to-get-newsletter-alerts-direct-to-your-inbox?utm_medium=ACQUISITIONS_STANDFIRST&utm_campaign=BN22326&utm_content=signup&utm_term=standfirst&utm_source=GUARDIAN_WEB">Sign up for the Breaking News US email to get newsletter alerts in your inbox</a></p></li></ul><p>A judge is expected to sentence OxyContin maker Purdue Pharma to forfeit $225m to the US justice department on Tuesday, clearing the way for the company to finalize <a href="https://www.theguardian.com/us-news/2025/nov/18/purdue-pharma-opioid-settlement-oxycontin">a settlement</a> of thousands of lawsuits it faces over its role in the opioid crisis.</p><p>The penalty was agreed to in a 2020 pact to resolve federal civil and criminal investigations it was facing. If the judge si...
Did this story change how you see things?
Stories like this only matter when people see them. Help us get verified journalism in front of more eyes.
The Verity Ledger curates verified investigative journalism from trusted sources only.
See our sourcesMost Read This Week
Report: Merck’s blockbuster cancer drug topped $200,000 a year under Trump
4/14: The Takeout with Major Garrett
Trump’s Memphis Crime Task Force Arrested Over 800 Immigrants, Records Show. Only 2% of the Arrests Were for Violent Crimes.
Bipartisan duo that pushed Swalwell, Gonzales to resign says other lawmakers may be next
White House ramps up pressure to pass crypto bill as Congress returns
